IngredientesSucrase is the common name for a family of hydrolytic enzymes that catalyze the breakdown of the disaccharide sucrose into its two constituent monosaccharides, glucose and fructose. Sucrases are digestive enzymes that catalyze the hydrolysis of sucrose to its component monosaccharides, fructose and glucose. Within enzyme biochemistry, two related but mechanistically distinct enzymes carry out this reaction:
The distinction in mechanism is precise: invertases and sucrases hydrolyze sucrose to give the same mixture of glucose and fructose; invertases cleave the O-C (fructose) bond, whereas the sucrases cleave the O-C (glucose) bond.
When used as an exogenous enzyme supplement or pharmaceutical product, sacrosidase — derived from yeast — functions as the active sucrase agent. Sacrosidase is an enzyme with the chemical name of β,D-fructofuranoside fructohydrolase. Its CAS registry number is 9001-57-4 and its EC number is 232-615-7.
The mammalian sucrase-isomaltase complex is a large integral membrane glycoprotein. The complete primary structure (1,827 amino acids) of rabbit intestinal pro-sucrase-isomaltase (pro-SI) was deduced from the sequence of a nearly full-length cDNA. Pro-SI is anchored in the membrane by a single 20 amino acid segment spanning the bilayer. There is a high degree of homology between the isomaltase and sucrase portions (41% amino acid identity), indicating that pro-SI evolved by partial gene duplication.
The sucrase-isomaltase complex (SI) of the small intestinal brush border membrane accounts for approximately 9–10% of the intrinsic protein. The sucrase-isomaltase complex is synthesized as a single, very long (Mr approximately 260,000) polypeptide chain (pro-SI, carrying the two sites of sucrase and isomaltase in an already enzymatically active form); pro-SI is processed into 'final' SI by pancreatic proteases.
The pharmaceutical (yeast-derived) form has a distinct molecular profile. It has been reported that the primary amino acid structure of this protein consists of 513 amino acids with an apparent molecular weight of 100,000 Da for the glycosylated monomer (range 66,000–116,000 Da). Reports also suggest that the protein exists in solution as a monomer, dimer, tetramer, and octomer ranging from 100,000 Da to 800,000 Da. It has an isoelectric point (pI) of 4.5.
Sucrase activity is present endogenously in the mammalian small intestinal brush border as the sucrase-isomaltase complex. The enzymes maltase, lactase, and sucrase-isomaltase, found in the brush border of the small intestine, further break down maltose and the dietary disaccharides lactose and sucrose into monosaccharides for absorption.
For exogenous, commercial purposes, the principal source of sucrase/invertase is the yeast Saccharomyces cerevisiae. The enzyme is derived from baker's yeast (Saccharomyces cerevisiae). S. cerevisiae, due to its high fermenting capability, is one of the yeasts used for the commercial production of extra- and intracellular invertases. Yeast produces a β-fructosidase type of invertase whereas the mold invertase is an α-glucosidase.
The mesophilic yeast Saccharomyces cerevisiae is by far the main source of enzyme for the commercial production of invert sugar. The yeast periplasmic invertase (SUC2) is a glycoprotein optimally active at pH 4.5–5.0 and 55–60°C.
Sucrase/invertase activity is also broadly distributed in the plant kingdom. Invertases catalyze the hydrolysis of sucrose to glucose and fructose, thereby playing a key role in primary metabolism and plant development. According to the optimum pH, invertases are classified into acid invertases and alkaline/neutral invertases, which share no sequence homology.
Sucrase is commercially available in several forms:
The enzyme sucrase was not identified or isolated as a discrete entity in traditional medicine; rather, the clinical consequences of its deficiency were observed empirically within certain populations long before the biochemistry was understood. The most historically significant context is among Inuit (Eskimo) peoples of the circumpolar Arctic, where the condition now recognized as congenital sucrase-isomaltase deficiency (CSID) was widespread.
The prevalence in Inuit people in Greenland has been estimated to be as high as 5%–10% in studies from 1972 and 1987. Traditional Inuit diets, which were predominantly composed of animal proteins and fats with minimal dietary sucrose or starch, would have substantially reduced the symptomatic burden of this genetic deficiency; the disorder became more clinically apparent as Western diets were introduced. The disorder prevents the body from absorbing particular sugars, especially sucrose, and generally presents after weaning with the introduction of sucrose-containing foods to an infant's diet.
Before the enzyme was isolated and characterized, baker's yeast was recognized empirically as a palliative intervention for sucrose intolerance. Individuals affected with this disorder may benefit from ingesting fresh baker's yeast, which exhibits sucrase activity, after sucrose ingestion. Researchers suggest that the yeast be taken on a full stomach as sucrase activity is much more effective when the gastric juices are diluted. This practice represented an early, unrefined form of enzyme replacement therapy, predating modern pharmacological preparations.
The systematic study of sucrase as an enzyme began in the context of 19th- and early 20th-century enzyme biochemistry. Invertase from yeast was among the first enzymes subjected to rigorous kinetic study; Emil Fischer's lock-and-key model of enzyme specificity was partly founded on observations of invertase acting on sucrose. The understanding of the mammalian sucrase-isomaltase complex as a brush-border enzyme emerged with advanced protein biochemistry in the latter decades of the 20th century. The pharmaceutical application of yeast-derived sacrosidase as an oral enzyme replacement therapy was approved by the FDA as an orphan drug, reflecting the rarity and medical need associated with CSID.
Sucrase-isomaltase consists of two enzymatic subunits: sucrase and isomaltase. The subunits originate from a polypeptide precursor, pro-SI. By heterodimerizing the two subunits, the sucrase-isomaltase complex is formed. The enzyme is anchored in the intestinal brush border membrane by a hydrophobic segment located near the N-terminus of the isomaltase subunit. Before the enzyme is anchored to the membrane, pro-SI is mannose-rich and glycosylated; it moves from the ER to the Golgi, where it becomes a protein complex that is N- and O-glycosylated.
Sucrase-isomaltase (SI) is an enterocyte-specific, brush-border enzyme that has little activity in crypt cells and maximal activity in low and mid villus cells. The substrate scope of the complex is broad: the enzyme's purpose is to digest dietary carbohydrates such as starch, sucrose, and isomaltose.
Sucrase-isomaltase belongs to glycoside hydrolase family 31 (GH31). Its catalytic mechanism proceeds via hydrolysis of the glycosidic bond in sucrose: The catalytic action of sacrosidase is initiated when it binds to a sucrose molecule. The enzyme has a specific active site that recognizes and binds to the disaccharide substrate. Once bound, sacrosidase facilitates the hydrolysis of the glycosidic bond between glucose and fructose.
The enzyme catalyzes the hydrolysis of the glycosidic bond in sucrose. This involves the cleavage of the bond, facilitated by the enzyme's acidic and basic side chains that aid in the protonation and deprotonation necessary for bond cleavage. The resulting monosaccharides, glucose and fructose, are released from the enzyme's active site. These monosaccharides are now free to be absorbed by the enterocytes and transported into the bloodstream for further metabolism.
For the plant/fungal invertase form, the mechanistic classification differs at the substrate-binding level. β-Fructofuranosidase (invertase) recognizes a β-fructofuranosyl residue and hydrolyzes substrates via a covalent fructosyl-enzyme intermediate. Sucrose α-glucosidase (sucrase) recognizes an α-glucopyranosyl residue and hydrolyzes the α-glucosidic linkages of sucrose and maltose.
In general, sucrose is hydrolyzed by glycoside hydrolases (GHs) to produce glucose and fructose, which are primary substrates for glycolysis. The liberated monosaccharides are absorbed through the enterocyte apical membrane via specific transporter proteins (GLUT5 for fructose, SGLT1 for glucose) and enter portal circulation. In this way, sucrase activity is a rate-determining step in the bioavailability of dietary sucrose-derived energy.
Sucrase-isomaltase also participates in the final steps of starch digestion. In view of their interaction, SI and MGAM (maltase-glucoamylase) regulate the final steps in starch digestion in the intestine, whereby SI assumes the major role by virtue of its predominant expression in the intestinal BBMs, while MGAM acts in auxiliary supportive fashion. The hydrolytic functions of SI and MGAM are responsible for almost all carbohydrates that are linked via α-1,2, α-1,4 and α-1,6 linkages and comprise the majority of the typical diet in humans.
Congenital sucrase-isomaltase deficiency (CSID) is a rare genetic disorder characterized by a deficiency of the sucrase-isomaltase (SI) enzyme complex within the brush border membrane of the small intestine. Mutations in the SI gene result in abnormal synthesis and/or incorrect transport of the SI enzyme. Patients with CSID generally have reduced sucrase activity, but levels of isomaltase activity range from absent to almost normal.
A deficiency in the SI enzyme can be present at birth (genetic) or acquired later, often in association with damage to the enteric brush-border membrane. Presenting symptoms are predominantly gastrointestinal: typical presenting symptoms were watery diarrhoea, abdominal pain and bloating, sometimes noticeably worse after ingestion of fruit.
The estimated prevalence of CSID is 0.05% to 0.2% in North America and Europe and 3% to 10% in the native populations of Greenland, Alaska and Canada, although prevalence varies by country and ethnic group and nationwide population studies reflecting actual prevalence are largely lacking in the literature. Although the condition is known to be highly prevalent (about 5%–10%) in several Inuit populations, the genetic basis for this has not been described until relatively recently; in the proband, researchers identified a novel, homozygous frameshift mutation, c.273_274delAG (p.Gly92Leufs*8), predicted to result in complete absence of a functional protein product.
In contrast to these earlier reports, more recent studies demonstrating that heterozygous carriers of SI variants also experience symptoms suggest that CSID may be more common than once believed. The true prevalence of CSID is likely underestimated due to a number of factors, including inconsistencies in nomenclature of the condition, diverse testing methodologies with unclear performance characteristics, the existence of multiple genomic abnormalities with broad phenotypic variability, symptom overlap with other gastrointestinal (GI) disorders, and lack of high-quality epidemiologic data in adults.
The most important clinical evidence for sacrosidase (yeast-derived sucrase) as a treatment for CSID comes from a pivotal randomized, double-blind trial published in the Journal of Pediatric Gastroenterology and Nutrition. The purpose of this study was to determine if sacrosidase, a liquid produced from Saccharomyces cerevisiae containing 6,000 IU of sucrase activity per mg protein, prevented symptoms of diarrhea, abdominal cramps, gas, and bloating in patients with CSID consuming a normal sucrose and carbohydrate-containing diet. Twenty-eight children (aged 5 months to 11 years) underwent a randomized, double-blind trial consisting of two phases: (1) three sucrose breath H₂ tests with three single-dose treatments (placebo, sacrosidase, and sacrosidase plus milk), and (2) a dose-response phase consisting of four multidose treatments, each for 10 days — full-strength sacrosidase, 1:10 dilution, 1:100 dilution, and 1:1000 dilution. The trial concluded that sacrosidase is a safe, effective, well-accepted treatment to prevent gastrointestinal symptoms in patients with CSID consuming a normal diet.
A multicenter review further confirmed the broad clinical picture: in two multicenter, double-blind, randomized trials of sacrosidase treatment, 81% of patients were asymptomatic while on an unrestricted diet.
A separate case series of six pediatric patients with confirmed congenital SI deficiency showed consistent results: all six patients showed little improvement following advice regarding dietary management, but experienced a marked reduction in symptoms with sacrosidase administration; no adverse events were reported. The conclusion of that study was that sacrosidase is an effective and well-tolerated treatment for patients with congenital SI deficiency.
A qualitative interview study conducted in conjunction with a longitudinal observational study enrolled 43 adult and pediatric CSID patients (n=8 adults, n=35 children/adolescents) who were taking sacrosidase for at least three consecutive months. After diagnosis and treatment with sacrosidase, participants reported considerable improvement in symptoms and health-related quality of life (HRQL), yet symptoms persist that continue to affect daily life, indicating areas of potential unmet need.
The evidence for sacrosidase in CSID is the strongest available for any sucrase supplementation indication. It is supported by randomized, double-blind, placebo-controlled trials, multicenter data, and regulatory approval. The patient population is small given the rarity of the disease, which limits statistical power, but the effect size is clinically meaningful. The safety and effectiveness of Sucraid for the treatment of sucrase deficiency, which is part of CSID, have been established in pediatric patients aged 5 months and older. Use of Sucraid for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients.
An active and growing body of research has examined the relationship between partial, heterozygous loss-of-function variants in the SI gene and the common condition of irritable bowel syndrome (IBS). Interestingly, the main symptoms of CSID overlap with those in irritable bowel syndrome (IBS), a common functional gastrointestinal disorder with unknown etiology. Recent advances in genetic screening of IBS patients have revealed rare SI gene variants that are associated with IBS.
A landmark study published in Gut sequenced SI exons in familial IBS cases and screened known CSID mutations across a broader IBS cohort. SI gene variants coding for disaccharidases with defective or reduced enzymatic activity predispose to IBS. The authors concluded that this may help the identification of individuals at risk, and contribute to personalising treatment options in a subset of patients.
A subsequent multicenter study provided further evidence: further evidence linking rare functionally deleterious SI variations to IBS susceptibility was provided. Research at the cellular and protein level characterized the phenotypes of IBS-associated SI mutants: the data demonstrate that the SI mutants can be categorized into three groups including immature, mature but slowly transported, and finally mature and properly transported but with reduced enzymatic activity.
More recently, a study in Gut (2024) examined genotype-directed dietary interventions: compelling evidence is accumulating for a role of SI variants in IBS, which holds potential for the management of IBS-D patients based on their genotype. Growing evidence suggests that individuals with SI variants may present later in life, with symptoms overlapping with those of irritable bowel syndrome. The presence of SI genetic variants may, either alone or in combination, affect enzyme activity and lead to symptoms of different severity.
Evidence linking SI gene variants to IBS susceptibility is emerging and accumulative but not yet definitive. Studies are largely genetic association analyses and functional cellular studies, with limited prospective clinical intervention data specifically targeting sucrase replacement in IBS patients with confirmed SI variants. Further research is needed to clarify the true prevalence of SI deficiency, the pathobiology of single SI heterozygous mutations, and to define optimal diagnostic and treatment algorithms in the pediatric population. The field is promising but awaits larger randomized trials of enzyme replacement specifically in genotype-stratified IBS populations.
Beyond congenital forms, the SI enzyme can be secondarily reduced in conditions that damage the intestinal brush border, such as celiac disease, Crohn's disease, infectious gastroenteritis, and following intestinal surgery. A deficiency in the SI enzyme can be present at birth (genetic) or acquired later, often in association with damage to the enteric brush-border membrane. However, the effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency. Thus, exogenous sucrase supplementation for acquired SI deficiency remains an area of unmet clinical research need.
Sucrase is incorporated into many over-the-counter multi-enzyme digestive supplement formulations marketed for general digestive comfort. Exogenous enzymes are derived from other animals, fungi, yeasts, or plants. However, there is no robust clinical evidence from well-designed randomized controlled trials supporting the use of sucrase supplementation to meaningfully enhance sucrose digestion in individuals without a demonstrable enzymatic deficiency. The physiological rationale — that supplemental luminal sucrase could augment endogenous enzyme activity — is plausible, but has not been substantiated by high-quality human trials in healthy or non-CSID populations.
This is the primary and best-established domain of sucrase activity. Sucrase function is crucial for maintaining stable blood sugar levels, supporting brain and muscle energy, and preventing fermentation of undigested sugars in the gut, which could otherwise cause bloating, gas, or diarrhea. When sucrase is absent or deficient, undigested sucrose reaches the large intestine where bacterial fermentation produces gas and osmotic diarrhea — the hallmark symptom cluster of CSID.
These findings will help understand the pathophysiology of carbohydrate malabsorption in functional gastrointestinal disorders, particularly in irritable bowel syndrome, in which gene variants of SI are implicated.
By converting sucrose into absorbable monosaccharides, sucrase is an upstream determinant of postprandial blood glucose responses. In CSID, sucrose fails to be absorbed and does not contribute to glycemic load; paradoxically, some studies in Greenlandic Inuit populations have explored whether SI loss-of-function might confer metabolic effects. Loss of sucrase-isomaltase function increases acetate levels and improves metabolic health in Greenlandic cohorts (as reported in Gastroenterology, 2021). Before prescribing Sucraid to diabetic patients, the physician should consider that Sucraid will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose. This represents a clinically relevant metabolic interaction that has direct implications in diabetic management.
In untreated pediatric CSID, chronic malabsorption of sucrose leads to significant nutritional consequences. Symptoms usually present after consumption of fruits, juices, grains, and starches, leading to failure to thrive and malnutrition. Effective sucrase replacement reverses malabsorption and restores normal nutrient assimilation and growth trajectories.
The FDA-approved prescription product provides the most precisely characterized dosing data from clinical studies:
Normally, half of the dose of Sucraid is taken just before a meal or snack and the other half is taken during the meal or snack. Do not mix Sucraid with fruit juice or hot beverages as they may reduce the effectiveness of Sucraid.
Sucraid should be refrigerated at 36°F–46°F (2°C–8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F–77°F (15°C–25°C) for up to 3 days (72 hours).
In the pivotal clinical research, sacrosidase was characterized as a liquid containing 6,000 IU of sucrase activity per mg protein. Commercial supplement-grade invertase is standardized in Sumner Units (SU) per gram. No clinical dosing data from rigorous trials exist for over-the-counter sucrase/invertase preparations in non-CSID populations.
Safety data from controlled clinical studies of the prescription formulation are the most rigorous available. The reported adverse reactions (number of patients) were as follows: abdominal pain (4), vomiting (3), nausea (2), diarrhea (2), constipation (2), insomnia (1), headache (1), nervousness (1), and dehydration (1). This profile was derived from 52 patients treated over studies lasting up to 54 months.
The most clinically important safety signal is the potential for hypersensitivity reactions. Hypersensitivity reactions (wheezing, rash, and pruritis) have been reported. A serious case documented in post-marketing surveillance involved severe wheezing in a pediatric patient with pre-existing asthma: severe wheezing 90 minutes after the second dose of sacrosidase necessitated admission into the ICU for a 4-year-old boy; the wheezing was probably caused by sacrosidase; he had asthma and was being treated with steroids; a skin test for sacrosidase was positive.
Sucraid should not be prescribed to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol). This is particularly important because the enzyme is derived from Saccharomyces cerevisiae (baker's yeast), and individuals with yeast allergies are at demonstrably elevated risk.
A documented pharmacokinetic interaction involves dilution in acidic beverages. Fruit juice decreases effects of sacrosidase. Minor/Significance Unknown. Reconstitution with fruit juice may decrease efficacy. The product labeling explicitly states: Do not mix Sucraid with fruit juice or take it with fruit juice.
As a protein enzyme, sacrosidase is denatured at elevated temperatures. DO NOT HEAT SOLUTIONS CONTAINING SUCRAID. Do not put Sucraid in warm or hot fluids. This is a stability consideration that affects both dosing efficacy and storage.
A specific metabolic interaction must be considered in patients with diabetes mellitus: before prescribing Sucraid to diabetic patients, the physician should consider that Sucraid will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose. This means that previously non-absorbable dietary sucrose becomes glycemically active upon treatment, potentially necessitating adjustment to diabetic management regimens.
The safety and effectiveness of Sucraid for the treatment of sucrase deficiency have been established in pediatric patients aged 5 months and older. Clinical trials of Sucraid did not include patients 65 years of age and older to determine if they respond differently. Extrapolation to elderly populations therefore lacks formal evidentiary support.
The effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency. Clinicians should bear this in mind when considering off-label use in conditions such as celiac disease, Crohn's disease, or post-infectious enteropathy, where acquired SI deficiency may occur.
The orphan drug sacrosidase oral solution (Sucraid) has been approved by the FDA for the treatment of congenital sucrose isomaltose malabsorption. Sucraid is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older. Sucraid is the only FDA-approved enzyme replacement therapy indicated for the treatment of sucrase deficiency, which is part of CSID. As a prescription drug, it is classified separately from the over-the-counter dietary supplement invertase/sucrase products, which are regulated under the Dietary Supplement Health and Education Act (DSHEA) in the United States and face no requirement to demonstrate clinical efficacy prior to marketing.
Condiciones de salud que sacarasa puede ayudar a apoyar.
Abdominal pain and bloating are cardinal symptoms of sucrase-isomaltase deficiency, driven by fermentation of undigested sucrose by colonic bacteria with production of gas. Clinical trials of sacrosidase in CSID patients demonstrate significant reductions in abdominal cramping and bloating. Multiple clinical reviews and patient cohort studies confirm abdominal discomfort as a core, clinically documented outcome of sucrase deficiency.
Sucrase (as sacrosidase) has robust clinical evidence specifically in pediatric populations with congenital sucrase-isomaltase deficiency (CSID). Randomized, double-blind trials in children aged 5 months to 11 years demonstrated that sacrosidase enzyme replacement resolves diarrhea and GI symptoms when a normal sucrose-containing diet is consumed. CSID typically manifests after weaning when sucrose-containing foods are introduced, making it primarily a childhood diagnosis.
Sucrase deficiency is a well-documented cause of chronic osmotic diarrhea. When the sucrase enzyme is absent or reduced, undigested sucrose accumulates in the small intestinal lumen, producing watery hyperosmolar diarrhea through osmotic effects and subsequent fermentation by colonic bacteria. Sacrosidase enzyme replacement therapy has been clinically shown to significantly reduce or eliminate diarrhea in sucrase-deficient patients.
Sucrase is one of the most abundant and functionally critical brush border digestive enzymes in the small intestine. Sucrase-isomaltase accounts for the final step of sucrose and branch-starch digestion; its deficiency—whether congenital or acquired—is the best-studied example of a clinically consequential digestive enzyme disorder. Sacrosidase is the only FDA-approved oral enzyme replacement therapy for a specific intestinal disaccharidase deficiency.
Sucrase deficiency represents a specific, enzyme-based food sensitivity to sucrose and sucrose-containing foods. Patients with CSID or partial sucrase-isomaltase deficiency exhibit adverse GI reactions to sucrose consumption that are reproducible and dose-dependent. The condition can be misidentified as a food allergy, but it is a carbohydrate maldigestion disorder confirmed by breath testing or enzyme assay.
Multiple peer-reviewed genetic studies have identified sucrase-isomaltase (SI) gene variants as risk factors for IBS, particularly IBS with diarrhea. Partial or hypomorphic SI deficiency produces symptoms—diarrhea, bloating, abdominal pain—that closely overlap with and are often misdiagnosed as IBS. A 2018 landmark study in Gut demonstrated that functional SI variants significantly increase IBS susceptibility in a large multi-center cohort.
Sistemas corporales que sacarasa puede ayudar a apoyar.
Volver